Long-acting HIV treatment benefits adults with barriers to daily pill taking and adolescents with suppressed HIV

NIH-funded research networks provide evidence on cabotegravir and rilpivirine in additional populations.
Source: National Institutes of Health (NIH) News Releases - Category: American Health Source Type: news